Cytosorbents Corporation
CTSO
$0.8923
-$0.0208-2.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.26M | 33.48M | 33.75M | 30.63M | 30.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.26M | 33.48M | 33.75M | 30.63M | 30.05M |
| Cost of Revenue | 9.18M | 8.72M | 8.32M | 7.10M | 6.19M |
| Gross Profit | 25.07M | 24.76M | 25.43M | 23.53M | 23.86M |
| SG&A Expenses | 35.19M | 34.58M | 35.43M | 37.07M | 38.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.45M | 49.63M | 50.66M | 53.74M | 56.00M |
| Operating Income | -16.19M | -16.15M | -16.92M | -23.12M | -25.95M |
| Income Before Tax | -11.44M | -17.68M | -22.29M | -20.10M | -26.96M |
| Income Tax Expenses | -1.69M | -1.69M | -1.69M | -813.70K | -813.70K |
| Earnings from Continuing Operations | -9.75 | -15.99 | -20.60 | -19.29 | -26.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.75M | -15.99M | -20.60M | -19.29M | -26.15M |
| EBIT | -16.19M | -16.15M | -16.92M | -23.12M | -25.95M |
| EBITDA | -14.65M | -14.61M | -15.35M | -21.54M | -24.35M |
| EPS Basic | -0.18 | -0.29 | -0.38 | -0.38 | -0.54 |
| Normalized Basic EPS | -0.13 | -0.20 | -0.26 | -0.25 | -0.35 |
| EPS Diluted | -0.18 | -0.29 | -0.38 | -0.38 | -0.54 |
| Normalized Diluted EPS | -0.14 | -0.20 | -0.26 | -0.25 | -0.35 |
| Average Basic Shares Outstanding | 232.51M | 224.21M | 217.91M | 209.75M | 199.67M |
| Average Diluted Shares Outstanding | 237.07M | 224.21M | 217.91M | 209.75M | 199.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |